Werewolf Therapeutics, an MPM investment, is an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
In February 2021, Occam placed Tim Trost as CFO at Werewolf. Prior to Werewolf, Trost held numerous CFO roles at Asklepios BioPharmaceutical (AskBio), Chimerix, Argos Therapeutics, and InteCardia. He took the company public shortly after joining.
